# US 11,298,400 B2 · Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,298,400 B2 - Document ID: US11298400B2 - Status: Granted - Kind: B2 - Application number: 16/410,639 - Filed: 2019-05-13 - Published: 2020-11-19 - Granted: 2022-04-12 - Earliest claimed: 2019-05-13 - Assignees: Nymox Corporation - Applicants: Nymox Corporation - Inventors: Paul Averback - Web page: https://patentgrep.com/patent/US11298400B2 ## CPC - A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} - A61P 13/08: of the prostate - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Disclosed are methods of enhancing the therapeutic efficacy of Fexapotide Triflutate (TF) in treating LUTS, both irritative and obstructive, that include administering a composition comprising FT at least twice over a period spanning more than one year. The methods are capable of providing an enhanced therapeutic effect in treating nocturia, and in improving urinary flow, when compared to the therapeutic effect achieved by administration of the same or twice the total amount of FT administered. ## Claims ### Claim 1 A method of enhancing the therapeutic efficacy of Fexapotide Triflutate (FT) in treating Lower Urinary Tract Symptoms (LUTS), comprising: (i) identifying a mammal having LUTS that does not also have benign prostatic hyperplasia (BPH); and (ii) first administering a composition comprising FT to the mammal; and subsequently administering a composition comprising FT to the mammal at least more than one year after the first administration. ### Claim 2 (depends on 1) The method of claim 1, wherein the method comprises administration of Fexapotide Triflutate and a carrier. ### Claim 3 (depends on 1) The method of claim 1, wherein the method comprises administration of Fexapotide Triflutate in a concentration of 2.5 mg/L. ### Claim 4 (depends on 1) The method of claim 1, wherein Fexapotide Triflutate is administered by a method selected from the group consisting of orally, subcutaneously, intradermally, intranasally, intravenously, intramuscularly, intrathecally, intranasally, intratumorally, topically, transrectally, transperitoneally, and transdermally. ### Claim 5 A method of treating irritative symptoms of mammals having Lower Urinary Tract Symptoms (LUTS), comprising: (a) identifying a mammal having irritative symptoms of LUTS that does not also have benign prostatic hyperplasia (BPH); (b) administering a first composition comprising Fexapotide Triflutate (FT) to the mammal; and (c) administering a second composition comprising FT to the mammal at least more than one year after administering the first composition. ### Claim 6 (depends on 5) The method of claim 5, wherein the irritative symptoms are selected from the group consisting of daytime urinary frequency, urgency, and nocturia. ### Claim 7 (depends on 6) The method of claim 6, wherein the irritative symptom is nocturia. ### Claim 8 (depends on 5) The method of claim 5, wherein FT is present in the first composition in a concentration of about 2.5 mg/l. ### Claim 9 (depends on 8) The method of claim 8, wherein FT is present in the second composition in a concentration of about 2.5 mg/l. ### Claim 10 (depends on 5) The method of claim 5, wherein the method provides an improvement in the mean difference from baseline nocturia scores to follow-up scores, as measured by the answer to question #7 in the International Prostate Symptom Score (IPSS) of from about 40% to about 60%, when compared to a placebo control, wherein the answer to question #7 indicates how many times over the past month the mammal had to awaken to urinate from the time he went to bed until the time he got up. ### Claim 11 (depends on 5) The method of claim 5, wherein the method provides an improvement in the mean difference from baseline nocturia scores to follow-up scores, as measured by the answer to question #7 in the IPSS, of from about 15% to about 25%, when compared to a administration of the same total amount of FT only once, wherein the answer to question #7 indicates how many times over the past month the mammal had to awaken to urinate from the time he went to bed until the time he got up. ### Claim 12 A method of treating obstructive symptoms of mammals with Lower Urinary Tract Symptoms (LUTS), comprising: (a) identifying a mammal having obstructive symptoms of LUTS that does not also have benign prostatic hyperplasia (BPH); (b) administering a first composition comprising Fexapotide Triflutate (FT) to the mammal; and (c) administering a second composition comprising FT to the mammal at least more than one year after administering the first composition. ### Claim 13 (depends on 12) The method of claim 12, wherein the obstructive symptoms are selected from the group consisting of straining, weak stream, intermittent stream, and incomplete emptying. ### Claim 14 (depends on 12) The method of claim 12, wherein FT is present in the first composition in a concentration of about 2.5 mg/l. ### Claim 15 (depends on 14) The method of claim 14, wherein FT is present in the second composition in a concentration of about 2.5 mg/l. ### Claim 16 (depends on 12) The method of claim 12, wherein the method provides an improvement in reducing the percentage of patients who were not able to urinate an adequate volume of urine (>125 mL) of from about 65% to about 85%, when compared to a placebo control. ### Claim 17 (depends on 12) The method of claim 12, wherein the method provides an improvement in reducing the percentage of patients who were not able to urinate an adequate volume of urine (>125 mL), of from about 81% to about 85%, when compared to administration of the same total amount of FT only once. ### Claim 18 (depends on 12) The method of claim 12, wherein the method provides an improvement in peak flow rate (Qmax) mean change from baseline of from about 100% to about 200%, when compared to a placebo control. ### Claim 19 (depends on 12) The method of claim 12, wherein the method provides an improvement in peak flow rate (Qmax) mean change from baseline, of from about 95% to about 105%, when compared to administration of the same total amount of FT only once.